FY2026 EPS Estimates for Kura Oncology Raised by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at Brookline Capital Management lifted their FY2026 earnings per share estimates for shares of Kura Oncology in a research report issued on Thursday, May 1st. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of $0.88 for the year, up from their prior forecast of $0.84. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology's FY2027 earnings at $3.09 EPS, FY2028 earnings at $5.92 EPS and FY2029 earnings at $12.20 EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million.

Several other equities research analysts have also recently issued reports on KURA. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Scotiabank cut their price objective on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research report on Tuesday, April 8th. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Kura Oncology currently has an average rating of "Moderate Buy" and a consensus target price of $23.89.

Kura Oncology Trading Down 2.6 %

Shares of NASDAQ KURA traded down $0.15 during midday trading on Monday, reaching $5.64. 1,437,984 shares of the stock were exchanged, compared to its average volume of 1,165,144. The stock has a market capitalization of $455.59 million, a P/E ratio of -2.39 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The company has a 50 day simple moving average of $6.67 and a 200 day simple moving average of $9.42. Kura Oncology has a twelve month low of $5.41 and a twelve month high of $23.48.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently modified their holdings of KURA. China Universal Asset Management Co. Ltd. boosted its position in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after acquiring an additional 1,750 shares in the last quarter. Rhumbline Advisers boosted its holdings in Kura Oncology by 2.0% in the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after purchasing an additional 1,923 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after purchasing an additional 2,076 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock valued at $120,000 after purchasing an additional 2,285 shares during the last quarter. Finally, MetLife Investment Management LLC raised its holdings in Kura Oncology by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 44,828 shares of the company's stock worth $390,000 after purchasing an additional 2,776 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.